Guaifenesin

證據等級: L5

預測適應症: 10 個

Guaifenesin: From Expectorant (Cough & Congestion) to Nasal Cavity Disease

One-Sentence Summary

Guaifenesin is a well-established expectorant traditionally used for symptomatic relief of cough and chest congestion by reducing airway mucus viscosity. The TxGNN model predicts it may be effective for Nasal Cavity Disease (including chronic rhinitis and sinusitis), with 1 clinical trial and 2 publications currently supporting this direction. The mechanistic rationale is strong due to direct overlap between guaifenesin's mucolytic action and the pathological core of nasal cavity disease, though the evidence base remains limited in volume and requires further validation.

Quick Overview

Item	Content
Original Indication	Expectorant for cough and chest congestion
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.98%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Guaifenesin (guaiacol glyceryl ether) is an expectorant that acts by stimulating secretory cells of the respiratory mucosa to increase the output of respiratory tract fluid, thereby reducing mucus viscosity and adhesiveness and facilitating ciliary clearance. Detailed pharmacological MOA data from DrugBank was not retrieved in this evidence pack. However, the in vitro mechanistic study by Seagrave et al. (PMID 23113953, 2012) directly demonstrated in primary human tracheal-bronchial epithelial cells that guaifenesin suppresses MUC5AC mucin expression and significantly improves mucociliary transport rate — representing the highest-quality mechanistic evidence currently available.

Nasal cavity disease — encompassing chronic rhinitis, sinusitis, and related conditions — shares a core pathological feature with guaifenesin's established respiratory indication: mucociliary dysfunction and mucus stasis. In chronic rhinitis and sinusitis, thickened, poorly cleared secretions perpetuate mucosal inflammation and obstruction; guaifenesin's ability to reduce secretion viscosity and enhance ciliary transport directly targets this underlying mechanism. The mechanistic bridge is therefore not inferential but demonstrably direct.

The most compelling clinical signal is NCT01364467, a completed Phase 2 pilot randomised controlled trial investigating oral guaifenesin specifically in paediatric chronic rhinitis. Supporting literature further documents clinical use of guaifenesin-containing regimens in cystic fibrosis–related sinusitis and in voice users with nasal allergic disease, corroborating real-world clinical relevance of this mechanistic connection across multiple upper-airway disease contexts.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01364467	Phase 2	Completed	30	14-day randomised, placebo-controlled, parallel-group trial of oral guaifenesin for chronic rhinitis in children aged 7–18. Primary endpoints include nasal symptom relief (SN-5 survey), nasal airway volume, and biophysical properties of nasal secretions. Direct and highly relevant to the TxGNN prediction; however, pilot study design and small sample size (n=30) limit statistical power and generalisability. Results require cautious interpretation pending a larger replication study.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9065342	1997	Review / Clinical Guidance	American Journal of Rhinology	Clinical management recommendations for chronic sinusitis in adult cystic fibrosis patients (22 patients, 8 surgical). Documents use of mucolytic agents including guaifenesin as part of sinusitis management, providing indirect clinical support for its nasal application in a mucus-overproduction context.
12487405	2002	Expert Review	Logopedics, Phoniatrics, Vocology	Treatment strategies for allergic respiratory conditions in professional voice users. Recommends decongestants combined with guaifenesin as a clinically preferred option over antihistamines for managing nasal secretion burden, supporting real-world utility in upper-airway allergic/inflammatory disease.

Singapore Market Information

Guaifenesin currently has no registered products with the Health Sciences Authority (HSA) in Singapore and is not commercially marketed in this jurisdiction. Compassionate use or importation arrangements would need to be assessed if clinical development is pursued.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert warnings, contraindications, and drug interaction data were not available in this evidence pack. Obtaining full safety documentation is a blocking prerequisite before any S1 safety evaluation can proceed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Guaifenesin's mucolytic mechanism directly and demonstrably addresses the core pathological feature of nasal cavity disease, and one completed Phase 2 pilot RCT (NCT01364467) provides proof-of-concept clinical evidence specifically in paediatric chronic rhinitis. The biological rationale is among the strongest in the predicted indication set. However, the sole clinical trial is a small-sample pilot study, the drug is not currently registered in Singapore, and critical safety data (package insert warnings, contraindications) remain unavailable.

To proceed, the following is needed:

Safety data retrieval (Blocking): Download and parse the product monograph/package insert (TFDA or equivalent) to obtain warnings, contraindications, and special population guidance before S1 safety evaluation
Mechanistic data confirmation: Obtain DrugBank MOA entry (DB00874) to formally document mechanism of action for regulatory submissions
Larger clinical evidence: Design or identify a Phase 2/3 RCT in adult and paediatric chronic rhinitis/sinusitis populations to replicate and expand on NCT01364467 with adequate statistical power
Systematic literature review: Conduct a comprehensive search across non-English sources (e.g., European and Asian registries) to capture any additional unpublished or regional evidence
Singapore regulatory pathway assessment: Evaluate HSA requirements for first-in-Singapore registration or clinical trial authorisation, given zero existing registrations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.